BMS-986258 (anti-TIM-3)

Our unique IND engine has helped us identify novel pathways and targets in immuno-oncology and other areas.

T-cell immunoglobulin and mucin domain-3 (TIM-3) is an immune checkpoint receptor that is known to limit the duration and magnitude of T-cell responses.

Collaboration Agreement

In 2018, BMS initiated clinical development for the first candidate under the immune checkpoint pathway discovery collaboration between the companies. This TIM-3 antibody, BMS-986258, is now in a Phase 1/2 trial as a single agent and in combination with OPDIVO®.